BerGenBio ASA Merges with Oncoinvent to Boost Cancer Innovation

Bergenbio Asa ( (BRRGF) ) has released its Q2 earnings. Here is a breakdown of the information Bergenbio Asa presented to its investors.

BerGenBio ASA is a clinical-stage biopharmaceutical company based in Norway, focusing on developing novel medicines for aggressive diseases, including advanced cancers and severe respiratory infections. In the first half of 2025, BerGenBio announced significant strategic changes, highlighted by a proposed merger with Oncoinvent ASA, a company specializing in radiopharmaceutical cancer therapies. This merger aims to combine BerGenBio’s capital resources with Oncoinvent’s oncology pipeline to enhance innovation in cancer treatment.

The financial results for the first half of 2025 showed an increase in operating revenues to NOK 4.7 million, primarily from the resale of unused stock from a discontinued study. Operating expenses decreased significantly to NOK 59.3 million, reflecting cost-containment measures following the closure of the BGBC016 trial. The company reported an operating loss of NOK 54.6 million, an improvement from the previous year’s loss of NOK 90.5 million.

BerGenBio’s strategic focus shifted following the discontinuation of its lead clinical study, BGBC016, which led to a comprehensive strategic review and the decision to merge with Oncoinvent ASA. The merger, approved in August 2025, is expected to be completed by September 2025, with a fully underwritten rights issue of NOK 130 million to follow. This strategic move is set to position the combined entity to advance in the field of radiopharmaceutical cancer therapies.

Looking ahead, the merger with Oncoinvent ASA is anticipated to provide the combined company with sufficient funding to pursue its pipeline into 2027. The management’s outlook is focused on leveraging the strengths of both companies to drive innovation and growth in cancer treatment therapies.